<DOC>
	<DOCNO>NCT00080080</DOCNO>
	<brief_summary>The purpose study determine antitumor activity ( response rate , time tumor progression , survival ) safety docetaxel combination talabostat patient advance non-small cell lung cancer ( NSCLC ) fail prior platinum-containing regimen .</brief_summary>
	<brief_title>Study Talabostat Docetaxel Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm Stage IIIb/IV NSCLC Failed relapse receive platinumcontaining chemotherapy regimen firstline therapy advance NSCLC Measurable disease ECOG Performance Status 0 1 Expected survival ≥12 week Provide write informed consent More 2 prior chemotherapy regimen Brain metastasis ( exception : patient resection and/or complete course cranial irradiation , worsen CNS symptom , discontinue corticosteroid indication least 1 month ) Any malignancy within 5 year immediately prior first dose study medication exception basal cell nonmetastatic squamous cell carcinoma skin , carcinoma insitu cervix The need chronic ( i.e. , &gt; 7 day ) oral intravenous corticosteroid therapy A history severe hypersensitivity reaction drug formulate polysorbate 80 A history myocardial infarction within 1 year study entry , CABG within 6 month study entry , severe congestive heart failure ( ejection fraction &lt; 30 % ) , history ventricular arrhythmia , uncontrolled cardiac arrhythmia Any comorbidity condition , opinion investigator , may interfere assessment procedure protocol Patients within 30 day chemotherapy , radiation therapy , immunotherapy , investigational medication NSCLC . Patients must recover side effect treatment order enrol . Pregnant lactating woman . Clinically significant laboratory abnormality , specifically : Total bilirubin ≥institutional upper limit normal ( ULN ) ; Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥1.5 x ULN concomitant alkaline phosphatase &gt; 2.5 x ULN ; Hepatitis B surface antigen antibody Hepatitis C ( antiHCV antibody ) ; Serum creatinine ≥2.0mg/dL ; Granulocytes &lt; 1500/μL platelet &lt; 100,000/μL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>